Literature DB >> 17974526

Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals.

F C Muñoz-Casares1, S Rufián, M J Rubio, E Lizárraga, C Díaz-Iglesias, E Aranda, R Ciria, J Muntané, P Barrios, J Torres-Melero, S González-Moreno, L González-Bayón, B Camps, P Bretcha, J Farré, G Ortega-Pérez, A Gómez-Portilla.   

Abstract

Peritoneal carcinomatosis, considered years ago as a final stage of unresectable cancer, can now be managed with curative intention by means of a radical cytoreductive surgical procedure with associated peritonectomy and intraperitoneal chemotherapy, as described by Sugarbaker. Malignant neoplasms such as mesothelioma and pseudomyxoma peritonei, ovarian and colon cancer nowadays are experiencing some new therapeutical approaches. Higher survival rates can be reached in ovarian cancer, which is commonly diagnosed in the presence of peritoneal carcinomatosis, using an optimal cytoreductive radical surgery with intraperitoneal chemotherapy. An actualised review of the treatment of advanced ovarian cancer and a proposal of a national multicentre protocol for the treatment of peritoneal carcinomatosis from ovarian cancer has been performed by a group of Spanish surgeons and oncologists dedicated to a therapeutical approach to this pathology.

Entities:  

Mesh:

Year:  2007        PMID: 17974526     DOI: 10.1007/s12094-007-0118-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  81 in total

Review 1.  Second-look laparotomy for epithelial ovarian cancer: a reappraisal.

Authors:  C S Chu; S C Rubin
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  Treatment of peritoneal carcinomatosis with intent to cure.

Authors:  F Cavaliere; P Perri; F Di Filippo; D Giannarelli; C Botti; M Cosimelli; M Tedesco; F Principi; L Laurenzi; R Cavaliere
Journal:  J Surg Oncol       Date:  2000-05       Impact factor: 3.454

3.  Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.

Authors:  Sebastián Rufián; Francisco C Muñoz-Casares; Javier Briceño; Carlos J Díaz; María J Rubio; Rosa Ortega; Rubén Ciria; Manuel Morillo; Enrique Aranda; Jordi Muntané; Carlos Pera
Journal:  J Surg Oncol       Date:  2006-09-15       Impact factor: 3.454

4.  Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma.

Authors:  G Begossi; S Gonzalez-Moreno; G Ortega-Perez; L J Fon; P H Sugarbaker
Journal:  Eur J Surg Oncol       Date:  2002-02       Impact factor: 4.424

5.  Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer.

Authors:  Song-Mee Cho; Hyun Kwon Ha; Jae Young Byun; Jae Mun Lee; Chan Joo Kim; Sung Eun Nam-Koong; Joon Mo Lee
Journal:  AJR Am J Roentgenol       Date:  2002-08       Impact factor: 3.959

6.  Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer.

Authors:  A-A K Tentes; G Tripsiannis; S K Markakidis; C N Karanikiotis; G Tzegas; G Georgiadis; K Avgidou
Journal:  Eur J Surg Oncol       Date:  2003-02       Impact factor: 4.424

Review 7.  Staging ovarian cancer: role of imaging.

Authors:  Fergus V Coakley
Journal:  Radiol Clin North Am       Date:  2002-05       Impact factor: 2.303

8.  Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin.

Authors:  Eelco de Bree; John Romanos; John Michalakis; Kostantinos Relakis; Vasilis Georgoulias; John Melissas; Dimitris D Tsiftsis
Journal:  Anticancer Res       Date:  2003 May-Jun       Impact factor: 2.480

Review 9.  Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts.

Authors:  D Elias; B Detroz; B Debaene; E Damia; B Leclercq; P Rougier; P Lasser
Journal:  Hepatogastroenterology       Date:  1994-06

10.  Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study.

Authors:  M Deraco; C R Rossi; E Pennacchioli; S Guadagni; D C Somers; N Santoro; F Raspagliesi; S Kusamura; M Vaglini
Journal:  Tumori       Date:  2001 May-Jun
View more
  6 in total

1.  Ascites do not affect the rate of complete cytoreductive surgery and prognosis in patients with primary ovarian cancer with ascites treated with hyperthermic intraperitoneal chemotherapy.

Authors:  Mingchen Ba; Hui Long; Xiangliang Zhang; Zhaofei Yan; Shuai Wang; Yinbing Wu; Yuanfeng Gong; Shuzhong Cui
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

2.  Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre.

Authors:  Álvaro Arjona-Sánchez; Francisco C Muñoz-Casares; Sebastián Rufián-Peña; Rafael Díaz-Nieto; Ángela Casado-Adam; María J Rubio-Pérez; Rosa Ortega-Salas
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

3.  SPARC ameliorates ovarian cancer-associated inflammation.

Authors:  Neveen A Said; Ahmed A Elmarakby; John D Imig; David J Fulton; Kouros Motamed
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

4.  Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  Alvaro Arjona-Sanchez; Francisco Cristobal Muñoz-Casares; Angela Casado-Adam; Juan Manuel Sánchez-Hidalgo; Maria Dolores Ayllon Teran; Rafael Orti-Rodriguez; Ana Cristina Padial-Aguado; Javier Medina-Fernández; Rosa Ortega-Salas; Gema Pulido-Cortijo; Auxiliadora Gómez-España; Sebastián Rufián-Peña
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

5.  The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer.

Authors:  Francisco C Muñoz-Casares; Sebastián Rufián; María J Rubio; Carlos J Díaz; Rafael Díaz; Angela Casado; Alvaro Arjona; María C Muñoz-Villanueva; Jordi Muntané
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

6.  Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2.

Authors:  Ya'nan Yang; Song Li; Yiting Sun; Di Zhang; Zeyi Zhao; Lian Liu
Journal:  Onco Targets Ther       Date:  2019-01-29       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.